EDIT vs. CRSP
Compare and contrast key facts about Editas Medicine, Inc. (EDIT) and CRISPR Therapeutics AG (CRSP).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: EDIT or CRSP.
Key characteristics
| EDIT | CRSP | |
|---|---|---|
| YTD Return | -66.83% | -21.85% |
| 1Y Return | -47.74% | 22.98% |
| 3Y Return (Ann) | -56.02% | -21.32% |
| 5Y Return (Ann) | -29.85% | 5.24% |
| Sharpe Ratio | -0.68 | 0.37 |
| Sortino Ratio | -0.89 | 1.00 |
| Omega Ratio | 0.91 | 1.11 |
| Calmar Ratio | -0.51 | 0.26 |
| Martin Ratio | -1.09 | 0.67 |
| Ulcer Index | 44.93% | 31.13% |
| Daily Std Dev | 72.71% | 57.31% |
| Max Drawdown | -96.73% | -81.61% |
| Current Drawdown | -96.29% | -76.71% |
Fundamentals
| EDIT | CRSP | |
|---|---|---|
| Market Cap | $273.00M | $4.11B |
| EPS | -$2.33 | -$3.20 |
| PEG Ratio | 0.00 | -0.21 |
| Total Revenue (TTM) | $61.70M | $201.02M |
| Gross Profit (TTM) | $57.40M | $72.25M |
| EBITDA (TTM) | -$158.56M | -$207.69M |
Correlation
The correlation between EDIT and CRSP is 0.67, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
EDIT vs. CRSP - Performance Comparison
In the year-to-date period, EDIT achieves a -66.83% return, which is significantly lower than CRSP's -21.85% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
EDIT vs. CRSP - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Editas Medicine, Inc. (EDIT) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
EDIT vs. CRSP - Dividend Comparison
Neither EDIT nor CRSP has paid dividends to shareholders.
Drawdowns
EDIT vs. CRSP - Drawdown Comparison
The maximum EDIT drawdown since its inception was -96.73%, which is greater than CRSP's maximum drawdown of -81.61%. Use the drawdown chart below to compare losses from any high point for EDIT and CRSP. For additional features, visit the drawdowns tool.
Volatility
EDIT vs. CRSP - Volatility Comparison
Editas Medicine, Inc. (EDIT) has a higher volatility of 16.52% compared to CRISPR Therapeutics AG (CRSP) at 8.03%. This indicates that EDIT's price experiences larger fluctuations and is considered to be riskier than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
EDIT vs. CRSP - Financials Comparison
This section allows you to compare key financial metrics between Editas Medicine, Inc. and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities